Key Points
- Director Kevin Bitterman executed large insider sales across October–December, selling about 367,708 shares for roughly $31.2 million, including a Dec. 12 sale of 45,507 shares at $92.39 that the filing said reduced his ownership by 52.29% (he held 41,519 shares after that sale).
- Analyst sentiment is mostly positive: one Strong Buy, ten Buys and one Sell give a MarketBeat consensus of "Moderate Buy" with a consensus price target of about $119, and several firms recently raised targets into the $109–$117 range.
- Company and stock context: Disc Medicine is a clinical-stage biopharma focused on hematologic diseases; the stock trades near $91.47 (12‑month range $30.82–$99.50, market cap ~$3.45B) and its most recent quarter showed an EPS loss of $1.77, missing estimates and with analysts forecasting a ~-4.07 EPS for the year.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider William Jacob Savage sold 13,093 shares of the firm's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $91.22, for a total value of $1,194,343.46. Following the completion of the transaction, the insider owned 75,702 shares of the company's stock, valued at approximately $6,905,536.44. This represents a 14.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Disc Medicine Price Performance
Disc Medicine stock opened at $91.47 on Wednesday. The firm has a market capitalization of $3.45 billion, a PE ratio of -17.10 and a beta of 0.87. Disc Medicine, Inc. has a 52 week low of $30.82 and a 52 week high of $99.50. The firm's 50-day simple moving average is $86.99 and its 200 day simple moving average is $68.22. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05.
Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). On average, equities research analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages recently issued reports on IRON. Wells Fargo & Company lifted their price objective on Disc Medicine from $91.00 to $109.00 and gave the stock an "overweight" rating in a research report on Tuesday. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a report on Wednesday, October 8th. Wedbush upped their price objective on Disc Medicine from $90.00 to $110.00 and gave the company an "outperform" rating in a research report on Friday, October 17th. Morgan Stanley lifted their price objective on Disc Medicine from $90.00 to $115.00 and gave the stock an "overweight" rating in a research report on Thursday, October 30th. Finally, National Bankshares set a $153.00 target price on shares of Disc Medicine in a research note on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $119.00.
View Our Latest Stock Analysis on IRON
Institutional Investors Weigh In On Disc Medicine
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Arizona State Retirement System grew its stake in shares of Disc Medicine by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 6,654 shares of the company's stock valued at $440,000 after buying an additional 120 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Disc Medicine by 2.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company's stock worth $469,000 after buying an additional 138 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Disc Medicine by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company's stock valued at $71,000 after acquiring an additional 181 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company's stock valued at $133,000 after acquiring an additional 206 shares during the period. Finally, HighVista Strategies LLC increased its stake in Disc Medicine by 4.3% during the second quarter. HighVista Strategies LLC now owns 6,733 shares of the company's stock worth $357,000 after acquiring an additional 275 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
